REGENXBIO to Engage in Influential Investor Conference
REGENXBIO Inc. (Nasdaq: RGNX), a leader in the biotechnology sector, has announced its participation in an upcoming investor conference designed to highlight the advancements and innovations in gene therapy. This conference is a valuable opportunity for investors to learn more about the exciting developments in the field.
Conference Details
The investor conference where REGENXBIO will present is the prestigious Piper Sandler 37th Annual Healthcare Conference. The company is scheduled to partake in a fireside chat on Tuesday, December 2 at 8:30 a.m. ET. This event will offer insights into the company’s vision, ongoing projects, and the future of gene therapies.
Live Webcast Availability
For those who cannot attend in person, a live webcast of the fireside chat will be accessible in the Investors section of REGENXBIO's official website. After the live event, an archived replay will be available for approximately 30 days, ensuring that those interested can catch up on the discussions at their convenience.
Understanding REGENXBIO Inc.
Founded in 2009, REGENXBIO is committed to harnessing the transformative potential of gene therapy to enhance lives. The company has positioned itself at the forefront of AAV (adeno-associated virus) gene therapy, pioneering innovative treatments aimed at addressing both rare and retinal diseases. Their portfolio includes a variety of promising therapies such as RGX-202 for treating Duchenne muscular dystrophy, clemidsogene lanparvovec (RGX-121) for MPS II, and RGX-111 for MPS I. Each of these treatments is developed in partnership with Nippon Shinyaku.
Collaborating for Progress
Additionally, REGENXBIO is collaborating with AbbVie on the investigational therapy surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy. With an impressive track record, thousands of patients have benefited from REGENXBIO's AAV platform, including groundbreaking treatments like Novartis’ ZOLGENSMA®.
The Future of Healthcare Delivery
REGENXBIO's investigational gene therapies are believed to hold the potential to revolutionize healthcare delivery for millions. As the company continues to innovate, its commitment to providing effective treatments remains strong. By attending conferences like the Piper Sandler event, REGENXBIO demonstrates its dedication to transparency and communication with stakeholders in the healthcare community.
Frequently Asked Questions
What is the purpose of REGENXBIO’s participation in the conference?
The participation highlights the company’s advancements in gene therapy, aiming to keep investors informed.
When is the fireside chat scheduled to take place?
The fireside chat is scheduled for Tuesday, December 2 at 8:30 a.m. ET.
Where can I access the webcast of the event?
The live webcast is available on REGENXBIO's official website in the Investors section.
What types of diseases is REGENXBIO focused on treating?
REGENXBIO primarily focuses on rare and retinal diseases through innovative gene therapies.
How long will the archived replay of the webcast be available?
The archived replay will be accessible for approximately 30 days following the event.